# FDA Inspection 1222624 - Balkanpharma Dupnitsa AD - September 29, 2023

Source: https://www.keypedia.com/records/fda_inspections/balkanpharma-dupnitsa-ad/0617b475-59cf-4eb8-b3df-7c4fba341ed6
Source feed: FDA_Inspections

> FDA Inspection 1222624 for Balkanpharma Dupnitsa AD on September 29, 2023. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1222624
- Company Name: Balkanpharma Dupnitsa AD
- Inspection Date: 2023-09-29
- Classification: No Action Indicated (NAI)
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [FDA Inspection 1140148 - 2019-03-01](https://www.keypedia.com/records/fda_inspections/balkanpharma-dupnitsa-ad/78d86b58-bc4e-422e-a427-e3b708fcd6a6)
- [FDA Inspection 1057710 - 2018-06-08](https://www.keypedia.com/records/fda_inspections/balkanpharma-dupnitsa-ad/97fc4add-f601-4cae-9797-37527a1df2a8)
- [FDA Inspection 945384 - 2015-08-28](https://www.keypedia.com/records/fda_inspections/balkanpharma-dupnitsa-ad/2c31f66a-4897-40e5-8cf0-474da9609e3f)

Company: https://www.keypedia.com/companies/balkanpharma-dupnitsa-ad/5cc89838-f87e-4692-a4a2-87d30a2b557b

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c